Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Japanese study of bilateral subretinal AAV5-hRKp.RPGR in RPGR-associated X-linked retinitis pigmentosa
jRCT2031230141Phase 3Active, not recruiting
- Sponsor
- MeiraGTx
- Start
- Jan 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of botaretigene sparoparvovec in X-linked retinitis pigmentosa (XLRP) and retinitis pigmentosa (RP), sponsored by MeiraGTx. Started Jan 2024; status: active, not recruiting.
02
Drugs
botaretigene sparoparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)retinitis pigmentosa (RP)
Beyond the preview
Go deeper on jRCT2031230141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230141.